The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
27774132 |
20 |
Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor. |
Takeda Pharmaceutical |
27720325 |
5 |
Novel approach of fragment-based lead discovery applied to renin inhibitors. |
Takeda Pharmaceutical |
27687967 |
17 |
Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors. |
Takeda Pharmaceutical |
26363506 |
44 |
Discovery of highly potent renin inhibitors potentially interacting with the S3' subsite of renin. |
China Pharmaceutical University |
25782742 |
76 |
trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: prime site exploration using an amino linker. |
Novartis Pharma |
25754490 |
44 |
trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: prime site exploration using an oxygen linker. |
Novartis Pharma |
25728416 |
25 |
Iminopyrimidinones: a novel pharmacophore for the development of orally active renin inhibitors. |
Merck Research Laboratories |
25086681 |
57 |
Structure-based optimization of non-peptidic Cathepsin D inhibitors. |
Merck |
25050166 |
58 |
Structure-based design of substituted piperidines as a new class of highly efficacious oral direct Renin inhibitors. |
Novartis Institutes For Biomedical Research |
25363711 |
62 |
Inhibitors of฿-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718). |
Amgen |
23993670 |
2 |
Novel BACE1 inhibitors with a non-acidic heterocycle at the P1' position. |
Kyoto Pharmaceutical University |
24054120 |
5 |
The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations. |
Novartis Institutes For Biomedical Research |
23886807 |
39 |
Synthesis and optimization of novel (3S,5R)-5-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)piperidine-3-carboxamides as orally active renin inhibitors. |
Daiichi Sankyo |
23598247 |
92 |
Lead optimization of 5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)-4-hydroxyhexanamides to reduce a cardiac safety issue: discovery of DS-8108b, an orally active renin inhibitor. |
Daiichi Sankyo |
23590342 |
105 |
ß-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease. |
F. Hoffmann-La Roche |
23425156 |
24 |
The discovery of novel potent trans-3,4-disubstituted pyrrolidine inhibitors of the human aspartic protease renin from in silico three-dimensional (3D) pharmacophore searches. |
Novartis Pharma |
23360239 |
19 |
A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophore. |
Novartis Pharma |
3316655 |
34 |
Renin inhibitors. Free-Wilson and correlation analysis of the inhibitory potency of a series of pepstatin analogues on plasma renin. |
Sanofi Recherche |
22200345 |
7 |
An integrated computational workflow for efficient and quantitative modeling of renin inhibitors. |
Sanofi Us |
| 4 |
Retro-Inverso Tripeptide Renin Inhibitors |
TBA |
23122821 |
26 |
Design and discovery of new (3S,5R)-5-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]piperidine-3-carboxamides as potent renin inhibitors. |
Daiichi Sankyo |
21381769 |
56 |
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. |
Universite£ |
24900544 |
8 |
Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor. |
TBA |
22621689 |
1 |
Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations. |
National Hellenic Research Foundation |
22726934 |
58 |
Design and optimization of novel (2S,4S,5S)-5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)-4-hydroxy-2-isopropylhexanamides as renin inhibitors. |
Daiichi Sankyo |
24900262 |
31 |
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility. |
TBA |
22450130 |
87 |
Design and synthesis of potent, isoxazole-containing renin inhibitors. |
Merck Frosst Centre For Therapeutic Research |
19715320 |
87 |
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. |
University of Florida |
19358611 |
103 |
Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors. |
Actelion Pharmaceuticals |
10669559 |
180 |
Protease inhibitors: current status and future prospects. |
University of Queensland |
8120867 |
70 |
Non-peptide renin inhibitors containing 2-(((3-phenylpropyl)phosphoryl)oxy)alkanoic acid moieties as P2-P3 replacements. |
E. Merck Darmstadt |
8474103 |
123 |
Potent and selective inhibitors of an aspartyl protease-like endothelin converting enzyme identified in rat lung. |
Abbott Laboratories |
8340909 |
14 |
Excursions in drug discovery. |
Merck Research Laboratories |
1433190 |
43 |
Highly potent, orally active diester macrocyclic human renin inhibitors. |
Merck Research Laboratories |
1635057 |
48 |
Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors. |
Parke-Davis Pharmaceutical Research Division of Warner-Lambert |
1732531 |
88 |
Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitors. |
Warner-Lambert |
2066983 |
10 |
Determination of dissociation constants of high affinity (pM) human renin inhibitors: application to analogues of ditekiren (U-71,038). |
Upjohn Laboratories |
2066966 |
32 |
Renin inhibitors containing esters at the P2-position. Oral activity in a derivative of methyl aminomalonate. |
Warner-Lambert |
2002469 |
80 |
Renin inhibitors containing conformationally restricted P1-P1' dipeptide mimetics. |
Merck Sharp and Dohme Research Laboratories |
1956045 |
88 |
Substrate analogue renin inhibitors containing replacements of histidine in P2 or isosteres of the amide bond between P3 and P2 sites. |
E. Merck Darmstadt |
2202828 |
28 |
Novel inhibitors of human renin. Cyclic peptides based on the tetrapeptide sequence Glu-D-Phe-Lys-D-Trp. |
Ici Pharmaceuticals Group |
2194033 |
33 |
Water-soluble renin inhibitors: design of a subnanomolar inhibitor with a prolonged duration of action. |
Abbott Laboratories |
2184238 |
14 |
Renin inhibitory peptides. A beta-aspartyl residue as a replacement for the histidyl residue at the P-2 site. |
Upjohn |
2120440 |
23 |
Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction. |
Kissei Pharmaceutical |
2566685 |
47 |
Inhibition of aminopeptidases by peptides containing ketomethylene and hydroxyethylene amide bond replacements. |
University of Wisconsin-Madison |
2657067 |
23 |
Azido glycols: potent, low molecular weight renin inhibitors containing an unusual post scissile site residue. |
Abbott Laboratories |
3045320 |
37 |
Design of rat renin inhibitory peptides. |
Massachusetts General Hospital |
3290486 |
7 |
Synthesis and renin inhibitory activity of angiotensinogen analogues having dehydrostatine, Leu psi [CH2S]Val, or Leu psi [CH2SO]Val at the P1-P1' cleavage site. |
Upjohn |
3290485 |
7 |
Conformationally constrained renin inhibitory peptides: gamma-lactam-bridged dipeptide isostere as conformational restriction. |
Upjohn |
3275777 |
34 |
Design, structure-activity, and molecular modeling studies of potent renin inhibitory peptides having N-terminal Nin-For-Trp (Ftr): angiotensinogen congeners modified by P1-P1' Phe-Phe, Sta, Leu psi[CH(OH)CH2]Val or leu psi[CH2NH]Val substitutions. |
Upjohn |
3298652 |
19 |
Novel renin inhibitors containing analogues of statine retro-inverted at the C-termini: specificity at the P2 histidine site. |
TBA |
3546690 |
7 |
alpha-Methylproline-containing renin inhibitory peptides: in vivo evaluation in an anesthetized, ganglion-blocked, hog renin infused rat model. |
TBA |
3118024 |
35 |
Optimization and in vivo evaluations of a series of small, potent, and specific renin inhibitors containing a novel Leu-Val replacement. |
Abbott Laboratories |
3543358 |
96 |
Pepstatin analogues as novel renin inhibitors. |
TBA |
3531518 |
17 |
Design and synthesis of a potent and specific renin inhibitor with a prolonged duration of action in vivo. |
TBA |
3531517 |
17 |
Design and synthesis of potent and specific renin inhibitors containing difluorostatine, difluorostatone, and related analogues. |
TBA |
3906131 |
61 |
Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine. |
TBA |
3906126 |
10 |
Difluorostatine- and difluorostatone-containing peptides as potent and specific renin inhibitors. |
TBA |
6352942 |
10 |
Inhibition of renin by angiotensinogen peptide fragments containing the hydroxy amino acid residue 5-amino-3-hydroxy-7-methyloctanoic acid. |
TBA |
7045370 |
8 |
Renin inhibitors. Substitution of the leucyl residues of Leu-Leu-Val-Phe-OCH3 with 3-amino-2-hydroxy-5-methylhexanoic acid. |
TBA |
6267277 |
15 |
Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension. |
TBA |
| 37 |
Peptidomimetic inhibitors of human immunodeficiency virus protease (HIV-PR): Design, enzyme binding and selectivity, antiviral efficacy, and cell permeability properties |
TBA |
22325946 |
36 |
3,4-Diarylpiperidines as potent renin inhibitors. |
Merck Frosst Center For Therapeutic Research |
22130130 |
19 |
Discovery of pyrrolidine-basedß-secretase inhibitors: lead advancement through conformational design for maintenance of ligand binding efficiency. |
Merck Research Laboratories |
22071301 |
115 |
Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines. |
Merck Frosst Centre For Therapeutic Research |
21641209 |
120 |
Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of tertiary alcohol-bearing piperidines. |
Merck Frosst Centre For Therapeutic Research |
21840218 |
62 |
Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors. |
Deutschland |
21840215 |
51 |
Structure-based design and optimization of potent renin inhibitors on 5- or 7-azaindole-scaffolds. |
Sanofi-Aventis Deutschland |
21741239 |
35 |
Biphenyl/diphenyl ether renin inhibitors: filling the S1 pocket of renin via the S3 pocket. |
Vitae Pharmaceuticals |
21708467 |
19 |
Synthesis, biological evaluation and docking studies of octane-carboxamide based renin inhibitors with extended segments toward S3' site of renin. |
China Pharmaceutical University |
21621998 |
110 |
Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines. |
Merck Frosst Centre For Therapeutic Research |
21497958 |
12 |
Potential virtual lead identification in the discovery of renin inhibitors: application of ligand and structure-based pharmacophore modeling approaches. |
Gyeongsang National University (Gnu) |
21429746 |
88 |
The discovery and synthesis of potent zwitterionic inhibitors of renin. |
Merck Frosst Centre For Therapeutic Research |
21112780 |
30 |
Design and synthesis of potent macrocyclic renin inhibitors. |
Medivir |
20731374 |
65 |
Direct renin inhibitors as a new therapy for hypertension. |
Novartis Pharmaceuticals |
20880704 |
200 |
Design and synthesis of aminohydantoins as potent and selective humanß-secretase (BACE1) inhibitors with enhanced brain permeability. |
Pfizer |
20850300 |
45 |
Discovery and optimization of a new class of potent and non-chiral indole-3-carboxamide-based renin inhibitors. |
Sanofi-Aventis Deutschland |
20843690 |
60 |
Piperidine-based renin inhibitors: upper chain optimization. |
Actelion Pharmaceuticals |
20843686 |
99 |
Design and optimization of new piperidines as renin inhibitors. |
Actelion Pharmaceuticals |
20728350 |
41 |
Identification of a new biaryl scaffold generating potent renin inhibitors. |
Merck Frosst Center For Therapeutic Research |
20673718 |
5 |
Addressing time-dependent CYP 3A4 inhibition observed in a novel series of substituted amino propanamide renin inhibitors, a case study. |
Merck Frosst Centre For Therapeutic Research |
20206513 |
35 |
Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension. |
Merck Frosst Centre For Therapeutic Research |
19853442 |
35 |
New classes of potent and bioavailable human renin inhibitors. |
Actelion Pharmaceuticals |
19959358 |
57 |
Optimization of orally bioavailable alkyl amine renin inhibitors. |
Vitae Pharmaceuticals |
19968289 |
201 |
Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors. |
Wyeth Research |
19757823 |
98 |
Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors. |
Wyeth Research |
19493591 |
7 |
Synthesis and evaluation of A-seco type triterpenoids for anti-HIV-1protease activity. |
University of Toyama |
19615901 |
52 |
The P1N-isopropyl motif bearing hydroxyethylene dipeptide isostere analogues of aliskiren are in vitro potent inhibitors of the human aspartyl protease renin. |
Nagasaki International University |
| 18 |
Design and synthesis of novel 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides as in vitro potent peptidomimetic inhibitors of human renin |
TBA |
| 23 |
Novel low molecular renin inhibitors which show good oral blood pressure lowering effects in marmosets |
TBA |
| 16 |
Bioactive hydroxyethylene dipeptide isosteres with hydrophobic (P3-P1)-moieties. A novel strategy towards small non-peptide renin inhibitors |
TBA |
| 3 |
Synthesis of α-hydroxy statine through a facially selective osmylation of a chiral α-amido crotonate |
TBA |
| 9 |
Rational design, synthesis, and X-ray structure of renin inhibitors with extended P1 sidechains |
TBA |
| 3 |
CP-71,362, an unusually potent inhibitor of rat and dog renin |
TBA |
| 11 |
Tetrahydroisoquinoline as a phenylalanine replacement in renin inhibitors |
TBA |
| 13 |
Preparation of a novel series of phosphonate norstatine renin inhibitors |
TBA |
| 4 |
Design and synthesis of a prototypical non-peptidic inhibitor model for the enzme renin |
TBA |
| 15 |
The identification of a novel renin inhibitor of equivalent efficacy following oral or intravenous administration. |
TBA |
| 22 |
Novel pseudosymmetric inhibitors of HIV-1 protease |
TBA |
| 24 |
Diol sulfonamides: A potent and novel class of inhibitors of human renin |
TBA |
| 6 |
Peptidomimetic inhibitors of renin incorporating topographically modified isosteres spanning the P1(→ P3)-P1' sites |
TBA |
| 12 |
MDL 74147, a novel selective and soluble inhibitor of human renin. Synthesis, structure-activity relationship, species and protease selectivities. |
TBA |
| 38 |
Conformationally restricted peptide isosteres. 2.1 Synthesis and in vitro potency of dipeptide renin inhibitors employing a 2-alkylsulfonyl-3-phenylcyclopropane carboxamide as a P3 amino acid replacement |
TBA |
19323562 |
14 |
2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects. |
Abbott Laboratories |
17482814 |
37 |
Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. |
Merck Research Laboratories |
16143527 |
32 |
Benzyl ether structure-activity relationships in a series of ketopiperazine-based renin inhibitors. |
Pfizer |
15837327 |
12 |
Equipotent activity in both enantiomers of a series of ketopiperazine-based renin inhibitors. |
Pfizer |
14741251 |
12 |
Rational design and synthesis of selective BACE-1 inhibitors. |
Merck Research Laboratories |
32247750 |
1 |
Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules. |
Annamalai University |
10360745 |
40 |
Piperidine-renin inhibitors compounds with improved physicochemical properties. |
F. Hoffmann-La Roche |
10360744 |
26 |
Substituted piperidines--highly potent renin inhibitors due to induced fit adaptation of the active site. |
F. Hoffmann-La Roche |
31589043 |
91 |
Discovery of AM-6494: A Potent and Orally Efficacious ?-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2. |
TBA |
31188592 |
39 |
Why Some Targets Benefit from beyond Rule of Five Drugs. |
Boston University |
8474102 |
29 |
Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3- [[(1-methylpiperazin-4-yl)sulfonyl]propionyl]-3-thiazol-4-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (A-725 |
Abbott Laboratories |
8474101 |
30 |
Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides. |
Abbott Laboratories |
8410992 |
35 |
Renin inhibitors containing a pyridyl amino diol derived C-terminus. |
Hoechst |
8410973 |
75 |
Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. |
University of Florida |
8254610 |
14 |
Analyses of ligand binding in five endothiapepsin crystal complexes and their use in the design and evaluation of novel renin inhibitors. |
Warner-Lambert |
7932521 |
81 |
Nonpeptide renin inhibitors with good intraduodenal bioavailability and efficacy in dog. |
Abbott Laboratories |
7752198 |
8 |
Time-resolved ligand exchange reactions: kinetic models for competitive inhibitors with recombinant human renin. |
Boehringer Ingelheim Pharmaceuticals |
7473584 |
16 |
alpha-Hydroxy phosphinyl-based inhibitors of human renin. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
6993683 |
8 |
N-(alpha-Hydroxyalkanoyl) derivatives of Leu-Val-Phe-OCH3 as inhibitors of renin. |
TBA |
6767029 |
14 |
Synthesis of analogues of the carboxyl protease inhibitor pepstatin. Effects of structure on inhibition of pepsin and renin. |
TBA |
6384520 |
9 |
Inhibition of renin by substrate analogue inhibitors containing the olefinic amino acid 5(S)-amino-7-methyl-3(E)-octenoic acid. |
TBA |
3906130 |
5 |
A uniquely potent renin inhibitor and its unanticipated plasma binding component. |
TBA |
3882966 |
28 |
Pepstatin-derived inhibitors of aspartic proteinases. A close look at an apparent transition-state analogue inhibitor. |
TBA |
3312604 |
33 |
Renin inhibitors based on novel dipeptide analogues. Incorporation of the dehydrohydroxyethylene isostere at the scissile bond. |
Abbott Laboratories |
3309316 |
50 |
Renin inhibitors. Statine-containing tetrapeptides with varied hydrophobic carboxy termini. |
Merck Sharp & Dohme Research Laboratories |
3309315 |
8 |
alpha,alpha-Difluoro-beta-aminodeoxystatine-containing renin inhibitory peptides. |
Upjohn |
3309313 |
48 |
Renin inhibitors. Dipeptide analogues of angiotensinogen incorporating transition-state, nonpeptidic replacements at the scissile bond. |
Abbott Laboratories |
3305947 |
7 |
Fluoro ketone containing peptides as inhibitors of human renin. |
TBA |
3305946 |
31 |
New inhibitors of human renin that contain novel Leu-Val replacements. |
TBA |
3302256 |
45 |
Analysis of structure-activity relationships in renin substrate analogue inhibitory peptides. |
TBA |
3295239 |
9 |
Renin inhibitors. Design of angiotensinogen transition-state analogues containing novel. (2R,3R,4R,5S)-5-amino-3,4-dihydroxy-2-isopropyl-7-methyloctanoic acid. |
TBA |
3279210 |
19 |
Renin inhibitors containing psi[CH2O] pseudopeptide inserts. |
Upjohn |
3279206 |
16 |
New inhibitors of human renin that contain novel Leu-Val replacements. Examination of the P1 site. |
Abbott Laboratories |
3276890 |
28 |
Renin inhibitors. Design and synthesis of a new class of conformationally restricted analogues of angiotensinogen. |
Abbott Laboratories |
3143010 |
28 |
Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a structurally modified phenylalanine residue to impart proteolytic stability. |
Abbott Laboratories |
3143009 |
50 |
Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency. |
Abbott Laboratories |
3137345 |
19 |
Synthesis and biological activity of some transition-state inhibitors of human renin. |
Ciba-Geigy |
3127587 |
33 |
New human renin inhibitors containing an unnatural amino acid, norstatine. |
Kissei Pharmaceutical |
3126296 |
43 |
Inhibition of porcine pepsin by two substrate analogues containing statine. The effect of histidine at the P2 subsite on the inhibition of aspartic proteinases. |
University of Wisconsin |
3050088 |
47 |
Renin inhibitors containing hydrophilic groups. Tetrapeptides with enhanced aqueous solubility and nanomolar potency. |
Merck Sharp & Dohme Research Laboratories |
28985999 |
74 |
Discovery of renin inhibitors containing a simple aspartate binding moiety that imparts reduced P450 inhibition. |
Glaxosmithkline |
2661820 |
18 |
Renin inhibitors. Synthesis of transition-state analogue inhibitors containing phosphorus acid derivatives at the scissile bond. |
Ciba-Geigy Pharmaceuticals Division |
2405159 |
49 |
Renin inhibitors containing isosteric replacements of the amide bond connecting the P3 and P2 sites. |
Warner-Lambert |
2404121 |
20 |
Renin inhibitors based on dipeptide analogues. Incorporation of the hydroxyethylene isostere at the P2/P3 sites. |
Abbott Laboratories |
2202829 |
18 |
Inhibitors of human renin. Cyclic peptide analogues containing a D-Phe-Lys-D-Trp sequence. |
Ici Pharmaceuticals Group |
2197411 |
13 |
Thermodynamics of the interaction of inhibitors with the binding site of recombinant human renin. |
Upjohn |
2187994 |
40 |
Potent, low molecular weight renin inhibitors containing a C-terminal heterocycle: hydrogen bonding at the active site. |
Abbott Laboratories |
29754833 |
73 |
Discovery of benzimidazole derivatives as orally active renin inhibitors: Optimization of 3,5-disubstituted piperidine to improve pharmacokinetic profile. |
Takeda Pharmaceutical |
2118184 |
14 |
1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 2. Synthesis, biological properties and molecular modeling of hydroxyethylene isostere derivatives. |
Ici Pharmaceuticals Group |
2118183 |
18 |
1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 1. Synthesis and biological properties of alkyl alcohol and statine derivatives. |
Ici Pharmaceuticals Group |
2105396 |
14 |
New inhibitors of renin that contain novel phosphostatine Leu-Val replacements. |
Abbott Laboratories |
28601508 |
34 |
Design, synthesis and biological evaluation of renin inhibitors guided by simulated annealing of chemical potential simulations. |
Bioleap |
1995887 |
14 |
Renin inhibitory peptides. Incorporation of polar, hydrophilic end groups into an active renin inhibitory peptide template and their evaluation in a human renin infused rat model and in conscious sodium-depleted monkeys. |
Upjohn |
1992151 |
10 |
Design of a well-absorbed renin inhibitor. |
Abbott Laboratories |
1992113 |
12 |
1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 3.1 Synthesis and biological properties of aminodeoxystatine and difluorostatone derivatives. |
Ici Pharmaceuticals Group |
1901910 |
87 |
New inhibitors of human renin that contain novel replacements at the P2 site. |
Warner-Lambert |
1895289 |
8 |
Design and synthesis of P2-P1'-linked macrocyclic human renin inhibitors. |
Merck Sharp and Dohme Research Laboratories |
1738148 |
16 |
Renin inhibitory pentols showing improved enteral bioavailability. |
Hoechst |
1597860 |
24 |
Renin inhibitors containing C-termini derived from mercaptoheterocycles. |
Merck Sharp & Dohme Research Laboratories |
1588555 |
83 |
C-terminal modifications of nonpeptide renin inhibitors: improved oral bioavailability via modification of physicochemical properties. |
Abbott Laboratories |
1588554 |
66 |
Nonpeptide renin inhibitors employing a novel 3-aza(or oxa)-2,4-dialkyl glutaric acid moiety as a P2/P3 amide bond replacement. |
Abbott Laboratories |
1588553 |
32 |
1,2,3-trisubstituted cyclopropanes as conformationally restricted peptide isosteres: application to the design and synthesis of novel renin inhibitors. |
University of Texas |
1552498 |
55 |
Renin inhibitors containing alpha-heteroatom amino acids as P2 residues. |
Warner-Lambert |
1548675 |
10 |
Synthesis and use of 3-amino-4-phenyl-2-piperidones and 4-amino-2-benzazepin-3-ones as conformationally restricted phenylalanine isosteres in renin inhibitors. |
Merck Sharp and Dohme Research Laboratories |
1548674 |
13 |
New modified heterocyclic phenylalanine derivatives. Incorporation into potent inhibitors of human renin. |
Wyeth-Ayerst Research |
1495010 |
19 |
Inhibitors of human renin with C-termini derived from amides and esters of alpha-mercaptoalkanoic acids. |
Merck Research Laboratories |
1404233 |
68 |
Renin inhibitors containing new P1-P1' dipeptide mimetics with heterocycles in P1'. |
E. Merck Darmstadt |
24072703 |
64 |
Structural determinants of Tau aggregation inhibitor potency. |
The Ohio State University |
10580501 |
2 |
Kainate receptors are involved in synaptic plasticity. |
University of Bristol |
9262370 |
33 |
I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. |
Neurogen |
12498885 |
9 |
Neoglycopeptides as inhibitors of oligosaccharyl transferase: insight into negotiating product inhibition. |
Massachusetts Institute of Technology |
17296300 |
14 |
Amphipathic benzoic acid derivatives: synthesis and binding in the hydrophobic tunnel of the zinc deacetylase LpxC. |
University of San Francisco |